CERo Therapeutics (CERO) Competitors $8.38 -0.29 (-3.34%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$8.32 -0.06 (-0.66%) As of 07/15/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO vs. ME, PMN, LPTX, ALVR, AIMD, BCLI, IMNN, NXTC, MTVA, and BTAIShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include 23andMe (ME), Promis Neurosciences (PMN), Leap Therapeutics (LPTX), AlloVir (ALVR), Ainos (AIMD), Brainstorm Cell Therapeutics (BCLI), Imunon (IMNN), NextCure (NXTC), MetaVia (MTVA), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. Its Competitors 23andMe Promis Neurosciences Leap Therapeutics AlloVir Ainos Brainstorm Cell Therapeutics Imunon NextCure MetaVia BioXcel Therapeutics 23andMe (NASDAQ:ME) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Do institutionals and insiders hold more shares of ME or CERO? 36.1% of 23andMe shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 26.3% of 23andMe shares are owned by company insiders. Comparatively, 12.7% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, ME or CERO? 23andMe has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Does the media refer more to ME or CERO? In the previous week, 23andMe had 13 more articles in the media than CERo Therapeutics. MarketBeat recorded 14 mentions for 23andMe and 1 mentions for CERo Therapeutics. CERo Therapeutics' average media sentiment score of 1.18 beat 23andMe's score of 0.10 indicating that CERo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 23andMe Neutral CERo Therapeutics Positive Is ME or CERO more profitable? CERo Therapeutics has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. CERo Therapeutics' return on equity of 0.00% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets 23andMe-183.39% -170.07% -62.13% CERo Therapeutics N/A N/A -199.71% Which has better earnings & valuation, ME or CERO? CERo Therapeutics has lower revenue, but higher earnings than 23andMe. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio23andMe$208.78M0.06-$666.70M-$15.45-0.03CERo TherapeuticsN/AN/A-$8.30MN/AN/A Do analysts rate ME or CERO? CERo Therapeutics has a consensus price target of $45.00, suggesting a potential upside of 436.99%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than 23andMe.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 23andMe 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryCERo Therapeutics beats 23andMe on 8 of the 14 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.35M$2.44B$5.62B$9.30BDividend YieldN/A1.79%4.25%4.03%P/E RatioN/A9.1428.5719.58Price / SalesN/A676.39423.3093.84Price / CashN/A164.3436.0257.93Price / Book-0.204.608.135.54Net Income-$8.30M$30.99M$3.24B$257.73M7 Day Performance-4.77%-1.81%0.16%-0.08%1 Month Performance21.98%5.73%5.95%8.09%1 Year Performance-97.85%-7.03%26.09%13.02% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo Therapeutics3.7917 of 5 stars$8.38-3.3%$45.00+437.0%-97.8%$3.35MN/A0.008Positive NewsME23andMeN/A$0.50-35.3%N/A-94.9%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumePMNPromis Neurosciences3.0886 of 5 stars$0.40-1.1%$4.50+1,013.0%-79.3%$13.22MN/A-8.095News CoverageAnalyst ForecastGap DownHigh Trading VolumeLPTXLeap Therapeutics2.2261 of 5 stars$0.32+12.0%$3.38+962.0%-84.6%$13.17MN/A-0.1940Positive NewsGap DownALVRAlloVirN/A$2.61+4.4%N/A-85.6%$13.16MN/A-0.13110AIMDAinos1.5593 of 5 stars$3.09-6.4%N/A-28.4%$12.95M$20K-0.4840BCLIBrainstorm Cell Therapeutics1.2785 of 5 stars$1.31+14.9%$30.00+2,190.1%-80.8%$12.89MN/A-0.3940High Trading VolumeIMNNImunon2.3288 of 5 stars$0.73-0.1%$15.50+2,025.0%-62.0%$12.80MN/A-0.5430Gap DownNXTCNextCure4.3506 of 5 stars$0.46+3.3%$3.50+668.2%+185.0%$12.78MN/A-0.2690Analyst ForecastMTVAMetaVia1.7322 of 5 stars$0.64+2.7%$7.50+1,074.4%N/A$12.51MN/A0.008BTAIBioXcel Therapeutics4.1989 of 5 stars$2.01+5.8%$42.60+2,019.4%-90.3%$12.18M$2.27M-0.1590Positive NewsGap Up Related Companies and Tools Related Companies ME Alternatives PMN Alternatives LPTX Alternatives ALVR Alternatives AIMD Alternatives BCLI Alternatives IMNN Alternatives NXTC Alternatives MTVA Alternatives BTAI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERO Stock Alerts